文献速递姑息放疗与转移瘤放疗物理与技术

癌症患者生命最后一年内的放射治疗使用情况

Use of Radiation Therapy Within the Last Year of Life Among Cancer Patients.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2018-01-31

单中心回顾性研究纳入870例在生命最后一年内至少有3次诊疗访视的癌症患者,分析其放疗使用情况。结果显示,生命最后一年内三分之一患者接受过放疗,且姑息性放疗在接近死亡时使用比例增加,尤其骨转移和单次分割放疗。

要点

  • 生命最后一年内三分之一患者接受放疗,最后180天降至24.3%,最后30天降至8.5%。
  • 姑息性放疗在接近死亡时使用增加,骨转移和单次分割放疗比例上升。

核心结论

  • 姑息性放疗在接近死亡时使用比例增加,照射部位中骨转移比例上升,可能与晚期癌症症状加重有关。

主要发现

  • 生命最后一年内三分之一患者接受放疗,共照射444个部位;最后180天和最后30天内接受放疗的比例分别降至24.3%和8.5%。
  • 接受放疗的患者死亡时更年轻,肺癌、肉瘤和移植疾病组比例更高。
  • 约四分之一照射部位为根治性意图,该比例在生命最后一年内保持恒定;姑息性放疗使用呈超线性增长,骨转移和单次分割放疗在接近死亡时增加。

临床怎么用

  • 对生命最后一年内的癌症患者,尤其是接近死亡者,应关注姑息性放疗特别是骨转移放疗的适用性,并认识到单次分割放疗使用增加的趋势。

局限性

  • 研究为单中心回顾性设计,预后极差(如30天内死亡)的患者通常不被纳入放疗临床试验,需进一步研究评估终末期骨转移姑息放疗的疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We examined radiation therapy (RT) use within the last year of life (LYOL). As palliative RT (PRT) has been well studied in patients with ≥6-week life expectancies, we hypothesized that PRT use would be constant over the LYOL, except for the last 30 days, when use would decline given lack of prospective data supporting it. MATERIALS AND METHODS: At a single institution, 870 cancer patients died between October 2, 2014, and September 30, 2015, and had ≥3 evaluation and management visits within the LYOL. Claims and RT data were extracted and linked. Over the LYOL, we evaluated RT use by intent (curative vs palliative) and indications. RESULTS: Within the LYOL, one-third of patients underwent RT in the last 365 days of life to 444 sites, which decreased to 24.3% and 8.5% in the last 180 and 30 days of life, respectively. Patients who received any RT in the last 365 days of life were younger at death and had a higher proportion of lung, sarcoma, and transplant disease groups. One-quarter of sites were irradiated with curative intent, which remained constant over the LYOL. In contrast, PRT was used at a supralinear rate, in which treatment of bone metastases and use of single-fraction PRT increased closer to death. CONCLUSIONS: PRT appears to be disproportionately used closer to death, with an increasing proportion of irradiated sites being bone metastases. This may be secondary to increased symptoms from advanced cancer toward the end of life. As patients with very poor prognoses (eg, within 30 days of death) are generally not included in RT clinical trials, further studies are warranted to assess whether PRT for bone metastases at the end of life is efficacious.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Tseng YD, Gouwens NW, Lo SS, et al. Use of Radiation Therapy Within the Last Year of Life Among Cancer Patients. Int J Radiat Oncol Biol Phys. 2018. PMID: 29487025. doi:10.1016/j.ijrobp.2018.01.056

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。